Edwards Lifesciences (EW) Stock Forecast & Price Target

$71.32 -0.06 (-0.08%)

Closing price 02/4/2025 03:59 PM Eastern

Extended Trading

$71.97 +0.65 (+0.91%)

As of 02/4/2025 06:50 PM Eastern

Edwards Lifesciences - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 26 Analyst Ratings

Sell
1

Hold
13

Buy
12

Based on 26 Wall Street analysts who have issued ratings for Edwards Lifesciences in the last 12 months, the stock has a consensus rating of "Hold." Out of the 26 analysts, 1 has given a sell rating, 13 have given a hold rating, and 12 have given a buy rating for EW.

Consensus Price Target

$79.19
11.03% Upside

According to the 26 analysts' twelve-month price targets for Edwards Lifesciences, the average price target is $79.19. The highest price target for EW is $105.00, while the lowest price target for EW is $60.00. The average price target represents a forecasted upside of 11.03% from the current price of $71.33.

Get the Latest News and Ratings for EW and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Edwards Lifesciences and its competitors.

EW Analyst Ratings Over Time

Type	Current Forecast 2/6/24 to 2/5/25	1 Month Ago 1/7/24 to 1/6/25	3 Months Ago 11/8/23 to 11/7/24	1 Year Ago 2/6/23 to 2/6/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	12 Buy rating(s)	11 Buy rating(s)	10 Buy rating(s)	8 Buy rating(s)
Hold	13 Hold rating(s)	15 Hold rating(s)	16 Hold rating(s)	8 Hold rating(s)
Sell	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$79.19	$79.40	$75.67	$84.19
Forecasted Upside	11.03% Upside	7.95% Upside	14.93% Upside	-4.60% Downside
Consensus Rating	Hold	Hold	Hold	Hold

EW Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

EW Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Edwards Lifesciences Stock vs. The Competition

Type	Edwards Lifesciences	Medical Companies	S&P 500
Consensus Rating Score	2.42	2.82	2.53
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	11.03% Upside	15,482.55% Upside	13.00% Upside
News Sentiment Rating	Positive News See Recent EW News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
1/30/2025	Stifel Nicolaus 4 of 5 stars	Rick Wise Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$75.00 ➝ $90.00	+26.39%
1/16/2025	Wolfe Research 3 of 5 stars	M. Polark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Peer Perform ➝ Underperform	$60.00 ➝ $60.00	-14.64%
12/16/2024	Bank of America 3 of 5 stars		Upgrade	Neutral ➝ Buy	$82.00 ➝ $90.00	+20.97%
12/11/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$81.00 ➝ $83.00	+13.00%
12/5/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$81.00 ➝ $90.00	+24.05%
12/5/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Hold ➝ Hold	$70.00 ➝ $78.00	+7.50%
12/5/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$80.00 ➝ $85.00	+16.82%
12/5/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$63.00 ➝ $68.00	-8.36%
12/2/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$85.00 ➝ $88.00	+25.37%
10/30/2024	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	N. Nakagiri Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
Get the Latest News and Ratings for EW and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter.
10/28/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Hambright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
10/25/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$72.00 ➝ $78.00	+13.04%
10/25/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$73.00 ➝ $70.00	+1.45%
10/25/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$73.00 ➝ $68.00	-3.29%
10/11/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Equal Weight	$70.00	+2.55%
10/1/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	In-Line ➝ In-Line	$76.00 ➝ $70.00	+6.69%
9/18/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$85.00 ➝ $70.00	+4.14%
9/12/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$90.00 ➝ $90.00	+34.71%
9/10/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$90.00 ➝ $75.00	+12.66%
9/9/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$90.00 ➝ $80.00	+19.47%
7/31/2024	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Outperform
7/25/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Rescott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/25/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Jennings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$100.00 ➝ $70.00	+14.27%
7/25/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$103.00 ➝ $85.00	+34.60%
4/11/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$95.00 ➝ $105.00	+14.78%
3/26/2024	OTR Global Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Mixed ➝ Positive
10/16/2023	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Kratky Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
10/16/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform	$75.00	+4.90%
6/27/2023	58.com Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Reiterates
2/6/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 01:42 AM ET.

Should I Buy Edwards Lifesciences Stock? EW Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, January 28, 2025. Please send any questions or comments about these Edwards Lifesciences pros and cons to contact@marketbeat.com.

Edwards Lifesciences
Bull Case

Here are some ways that investors could benefit from investing in Edwards Lifesciences Co.:

The company reported a strong net margin of 70.82%, indicating high profitability relative to its revenue, which can be attractive for investors seeking companies with solid financial health.
Edwards Lifesciences Co. has a market capitalization of $40.82 billion, suggesting it is a well-established player in the medical research sector, which can provide stability for investors.
With a current stock price of $69.21, the shares are trading below their 52-week high of $96.12, potentially offering a buying opportunity for investors looking for growth as the stock may rebound.
The company has a quick ratio of 2.89 and a current ratio of 3.46, both of which indicate strong liquidity and the ability to cover short-term obligations, making it a safer investment choice.
Analysts expect Edwards Lifesciences Co. to post earnings per share of 2.56 for the current year, reflecting positive growth expectations that could lead to stock price appreciation.

Edwards Lifesciences
Bear Case

Investors should be bearish about investing in Edwards Lifesciences Co. for these reasons:

The company reported revenue of $1.35 billion for the latest quarter, which fell short of analyst estimates of $1.57 billion, indicating potential challenges in meeting market expectations.
Insider selling activity has been noted, with significant shares sold recently, which could signal a lack of confidence from those closest to the company.
The price-to-earnings ratio of 9.99, while seemingly low, may suggest that the stock is undervalued, but it could also indicate that investors are cautious about future growth prospects.
With a beta of 1.11, the stock is slightly more volatile than the market, which could lead to greater risk for investors during market fluctuations.
Recent downgrades from analysts, including a reduction in price targets, may reflect a bearish sentiment that could impact investor confidence and stock performance.

EW Forecast - Frequently Asked Questions

: According to the research reports of 26 Wall Street equities research analysts, the average twelve-month stock price forecast for Edwards Lifesciences is $79.19, with a high forecast of $105.00 and a low forecast of $60.00.
: 26 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There is currently 1 sell rating, 13 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" EW shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EW, but not buy additional shares or sell existing shares.
: According to analysts, Edwards Lifesciences's stock has a predicted upside of 11.03% based on their 12-month stock forecasts.
: Over the previous 90 days, Edwards Lifesciences's stock had 2 upgrades and 1 downgrade by analysts.
: Edwards Lifesciences has been rated by research analysts at Bank of America, Barclays, Canaccord Genuity Group, Citigroup, Royal Bank of Canada, Stifel Nicolaus, The Goldman Sachs Group, Truist Financial, and Wolfe Research in the past 90 days.
: Analysts like Edwards Lifesciences less than other "medical" companies. The consensus rating for Edwards Lifesciences is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how EW compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

This page (NYSE:EW) was last updated on 2/5/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Edwards Lifesciences (EW) Stock Forecast & Price Target